Predictive factors of response in lung metastases treated by sbrt from colon rectal cancer.

IF 3.7 3区医学 Q2 ONCOLOGY

Clinical & Experimental Metastasis Pub Date : 2026-03-18 DOI:10.1007/s10585-026-10402-4

Donatella Caivano, D Pezzulla, P Bonome, F Palmeri, C Scaringi, M Valeriani, D Musio, V de Sanctis, M F Osti

{"title":"Predictive factors of response in lung metastases treated by sbrt from colon rectal cancer.","authors":"Donatella Caivano, D Pezzulla, P Bonome, F Palmeri, C Scaringi, M Valeriani, D Musio, V de Sanctis, M F Osti","doi":"10.1007/s10585-026-10402-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To identify predictive factors of response in patients with lung metastases from primary colorectal cancer (CRC) treated with stereotactic body radiation therapy (SBRT). This retrospective, single-centre study included patients with histologically confirmed primary CRC, Karnofsky performance status > 60, and age > 18 years. Between 2008 and 2023, 149 lung metastases in 88 patients were treated with SBRT. Among the treated lesions, 23 were synchronous and 126 were metachronous. According to a simplified oligometastatic classification, 9 (6%) were synchronous, 57 (38%) oligorecurrent, 76 (51%) oligoprogressive, and 7 (5%) oligopersistent. Local control (LC) at 1 and 2 years was 76.8% and 64.0%, respectively. Time to polymetastatic conversion (tPMC) at 1 and 2 years was 76.0% and 73.0%. Progression-free survival (PFS) at 1 and 2 years was 76.0% and 73.0%. Overall survival (OS) at 1 and 2 years was 80.7% and 53.0%. On multivariate analysis (MVA), lesion diameter < 16 mm was the only statistically significant favorable prognostic factor for LC. No statistically significant prognostic factors were identified for tPMC or PFS on MVA. For OS, ECOG performance status 0 and female sex were the only statistically significant favorable prognostic factors on MVA. No toxicities ≥ grade 3 were reported. Outcomes and prognostic factors reported herein refer to the present single-centre cohort. In this cohort, SBRT was feasible and was associated with acceptable toxicity and encouraging local control in lung metastases from CRC. Further studies are needed to better define predictive factors and support tailored therapeutic strategies.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"43 2","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Experimental Metastasis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10585-026-10402-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To identify predictive factors of response in patients with lung metastases from primary colorectal cancer (CRC) treated with stereotactic body radiation therapy (SBRT). This retrospective, single-centre study included patients with histologically confirmed primary CRC, Karnofsky performance status > 60, and age > 18 years. Between 2008 and 2023, 149 lung metastases in 88 patients were treated with SBRT. Among the treated lesions, 23 were synchronous and 126 were metachronous. According to a simplified oligometastatic classification, 9 (6%) were synchronous, 57 (38%) oligorecurrent, 76 (51%) oligoprogressive, and 7 (5%) oligopersistent. Local control (LC) at 1 and 2 years was 76.8% and 64.0%, respectively. Time to polymetastatic conversion (tPMC) at 1 and 2 years was 76.0% and 73.0%. Progression-free survival (PFS) at 1 and 2 years was 76.0% and 73.0%. Overall survival (OS) at 1 and 2 years was 80.7% and 53.0%. On multivariate analysis (MVA), lesion diameter < 16 mm was the only statistically significant favorable prognostic factor for LC. No statistically significant prognostic factors were identified for tPMC or PFS on MVA. For OS, ECOG performance status 0 and female sex were the only statistically significant favorable prognostic factors on MVA. No toxicities ≥ grade 3 were reported. Outcomes and prognostic factors reported herein refer to the present single-centre cohort. In this cohort, SBRT was feasible and was associated with acceptable toxicity and encouraging local control in lung metastases from CRC. Further studies are needed to better define predictive factors and support tailored therapeutic strategies.

查看原文本刊更多论文

结肠直肠癌肺转移瘤经sbrt治疗后疗效的预测因素

目的：探讨立体定向全身放射治疗（SBRT）对原发性结直肠癌（CRC）肺转移患者疗效的预测因素。这项回顾性的单中心研究纳入了组织学证实的原发性结直肠癌患者，Karnofsky表现状态为60岁，年龄为18岁。2008年至2023年间，88例患者中的149例肺转移患者接受了SBRT治疗。在治疗的病变中，同步病变23例，异时病变126例。根据简化的寡转移分类，9例（6%）为同步型，57例（38%）为寡复发型，76例（51%）为寡进展型，7例（5%）为寡持续型。1年和2年的局部控制率分别为76.8%和64.0%。1年和2年到多转移性转化（tPMC）的时间分别为76.0%和73.0%。1年和2年的无进展生存率（PFS）分别为76.0%和73.0%。1年和2年总生存率（OS）分别为80.7%和53.0%。在多变量分析（MVA）上，病变直径

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical & Experimental Metastasis 医学-肿瘤学

CiteScore

7.80

自引率

5.00%

发文量

审稿时长

12 months

期刊介绍： The Journal''s scope encompasses all aspects of metastasis research, whether laboratory-based, experimental or clinical and therapeutic. It covers such areas as molecular biology, pharmacology, tumor biology, and clinical cancer treatment (with all its subdivisions of surgery, chemotherapy and radio-therapy as well as pathology and epidemiology) insofar as these disciplines are concerned with the Journal''s core subject of metastasis formation, prevention and treatment.